Sihtmärkravi (Estonian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sihtmärkravi" in Estonian language version.

refsWebsite

Global rank Estonian rank

41worldcat.org

5^th place

76^th place

39doi.org

2^nd place

16^th place

31nih.gov

4^th place

14^th place

23europa.eu

68^th place

18^th place

9nature.com

234^th place

88^th place

4mdpi.com

2,912^th place

1,356^th place

2web.archive.org

1^st place

2cancer.gov

1,684^th place

1,186^th place

2ravimiregister.ee

low place

4,042^nd place

2utlib.ee

low place

90^th place

1frontiersin.org

4,679^th place

866^th place

1mycancergenome.org

low place

1cancercouncil.com.au

low place

1cancer.org

3,680^th place

2,604^th place

1ejcancer.com

low place

1macmillan.org.uk

low place

1aafp.org

1,916^th place

4,197^th place

1cell.com

2,814^th place

1,401^st place

1sciencedirect.com

149^th place

130^th place

1amegroups.com

low place

1futuremedicine.com

low place

1illumina.com

low place

1epikoda.ee

low place

1vahigeenid.ee

low place

1mu.ee

low place

1,570^th place

1kliinikum.ee

low place

183^rd place

1astrazeneca.com

low place

1postimees.ee

3,149^th place

4^th place

1delfi.ee

2,998^th place

3^rd place

1kingitudelu.ee

low place

5,633^rd place

aafp.org

Gerber, David E. (1. veebruar 2008). "Targeted Therapies: A New Generation of Cancer Treatments". American Family Physician (Ameerika inglise). 77 (3): 311–319.

amegroups.com

tlcr.amegroups.com

Stewart, Erin L.; Tan, Samuel Zhixing; Liu, Geoffrey; Tsao, Ming-Sound (2015). "Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review". Translational Lung Cancer Research (inglise). 4 (1). DOI:10.3978/j.issn.2218-6751.2014.11.06. ISSN 2226-4477.

astrazeneca.com

AstraZeneca (26. oktoober 2022). "Capivasertib plus Faslodex significantly improved progression-free survival vs. Faslodex in CAPItello-291 Phase III trial in advanced HR-positive breast cancer". astrazeneca.com. Vaadatud 11.02.2023.

cancer.gov

"Targeted Therapy for Cancer - NCI". www.cancer.gov (inglise). 15. august 2014. Vaadatud 5. veebruaril 2023.
"Milestones in Cancer Research and Discovery - NCI". www.cancer.gov (inglise). 21. jaanuar 2015. Vaadatud 11. veebruaril 2023.

cancer.org

"Targeted Cancer Therapy | Targeted Drug Therapy for Cancer". www.cancer.org (inglise). Vaadatud 5. veebruaril 2023.

cancercouncil.com.au

"Types of targeted therapy". Cancer Council NSW (Ameerika inglise). Vaadatud 5. veebruaril 2023.

cell.com

Brown, Wells S.; McDonald, Paul C.; Nemirovsky, Oksana; Awrey, Shannon; Chafe, Shawn C.; Schaeffer, David F.; Li, Jinyang; Renouf, Daniel J.; Stanger, Ben Z.; Dedhar, Shoukat (17. november 2020). "Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer". Cell Reports Medicine (English). 1 (8). DOI:10.1016/j.xcrm.2020.100131. ISSN 2666-3791. PMID 33294856.{{ajakirjaviide}}: CS1 hooldus: tundmatu keel (link)

delfi.ee

naistekas.delfi.ee

"Lasteonkoloog Kadri Saks: rõõm on tõdeda, et me suudame terveks ravida ka väga raskelt haigeid lapsi". Naistekas. Vaadatud 11. veebruaril 2023.

doi.org

Martinelli, E.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. (2009). "Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy". Clinical and Experimental Immunology. 158 (1): 1–9. DOI:10.1111/j.1365-2249.2009.03992.x. ISSN 1365-2249. PMC 2759052. PMID 19737224.
Falzone, Luca; Salomone, Salvatore; Libra, Massimo (2018). "Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium". Frontiers in Pharmacology. 9. DOI:10.3389/fphar.2018.01300/full. ISSN 1663-9812.
Baudino, Troy A. (2015). "Targeted Cancer Therapy: The Next Generation of Cancer Treatment". Current Drug Discovery Technologies. 12 (1): 3–20. DOI:10.2174/1570163812666150602144310. ISSN 1875-6220. PMID 26033233.
Phelps, Mitch A. (11. mai 2017). "Rituximab immunotherapy: it's getting personal". Blood. 129 (19): 2595–2596. DOI:10.1182/blood-2017-03-772061. ISSN 1528-0020. PMID 28495922.
Jordan, V. Craig (1. jaanuar 2008). "Tamoxifen: Catalyst for the change to targeted therapy". European Journal of Cancer (English). 44 (1): 30–38. DOI:10.1016/j.ejca.2007.11.002. ISSN 0959-8049.{{ajakirjaviide}}: CS1 hooldus: tundmatu keel (link)
Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong (31. mai 2021). "Small molecules in targeted cancer therapy: advances, challenges, and future perspectives". Signal Transduction and Targeted Therapy (inglise). 6 (1): 1–48. DOI:10.1038/s41392-021-00572-w. ISSN 2059-3635.
Constantinescu, Catalin; Pasca, Sergiu; Zimta, Alina-Andreea; Tat, Tiberiu; Rus, Ioana; Teodorescu, Patric; Iluta, Sabina; Tanase, Alina; Colita, Anca; Sigurjonsson, Olafur; Einsele, Hermann; Tomuleasa, Ciprian (2020). "Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies". Journal of Clinical Medicine (inglise). 9 (9): 2903. DOI:10.3390/jcm9092903. ISSN 2077-0383.
Brown, Wells S.; McDonald, Paul C.; Nemirovsky, Oksana; Awrey, Shannon; Chafe, Shawn C.; Schaeffer, David F.; Li, Jinyang; Renouf, Daniel J.; Stanger, Ben Z.; Dedhar, Shoukat (17. november 2020). "Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer". Cell Reports Medicine (English). 1 (8). DOI:10.1016/j.xcrm.2020.100131. ISSN 2666-3791. PMID 33294856.{{ajakirjaviide}}: CS1 hooldus: tundmatu keel (link)
Bhullar, Khushwant S.; Lagarón, Naiara Orrego; McGowan, Eileen M.; Parmar, Indu; Jha, Amitabh; Hubbard, Basil P.; Rupasinghe, H. P. Vasantha (19. veebruar 2018). "Kinase-targeted cancer therapies: progress, challenges and future directions". Molecular Cancer. 17 (1): 48. DOI:10.1186/s12943-018-0804-2. ISSN 1476-4598. PMC 5817855. PMID 29455673.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Waring, Michael J. (15. mai 2009). "Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability". Bioorganic & Medicinal Chemistry Letters. 19 (10): 2844–2851. DOI:10.1016/j.bmcl.2009.03.109. ISSN 1464-3405. PMID 19361989.
Zahavi, David; Weiner, Louis (2020). "Monoclonal Antibodies in Cancer Therapy". Antibodies (inglise). 9 (3): 34. DOI:10.3390/antib9030034. ISSN 2073-4468.
Tangutoori, Shifalika; Baldwin, Paige; Sridhar, Srinivas (2015). "PARP inhibitors: A new era of targeted therapy". Maturitas. 81 (1): 5–9. DOI:10.1016/j.maturitas.2015.01.015. ISSN 1873-4111. PMID 25708226.
Perini, Guilherme Fleury; Ribeiro, Glaciano Nogueira; Pinto Neto, Jorge Vaz; Campos, Laura Tojeiro; Hamerschlak, Nelson (11. mai 2018). "BCL-2 as therapeutic target for hematological malignancies". Journal of Hematology & Oncology. 11 (1): 65. DOI:10.1186/s13045-018-0608-2. ISSN 1756-8722. PMC 5946445. PMID 29747654.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Cheng, Yuan; He, Cai; Wang, Manni; Ma, Xuelei; Mo, Fei; Yang, Shengyong; Han, Junhong; Wei, Xiawei (17. detsember 2019). "Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials". Signal Transduction and Targeted Therapy (inglise). 4 (1): 1–39. DOI:10.1038/s41392-019-0095-0. ISSN 2059-3635.
Huang, Lamei; Guo, Zhixing; Wang, Fang; Fu, Liwu (15. november 2021). "KRAS mutation: from undruggable to druggable in cancer". Signal Transduction and Targeted Therapy (inglise). 6 (1): 1–20. DOI:10.1038/s41392-021-00780-4. ISSN 2059-3635.
Nguyen, Ngoc Minh; Cho, Jungsook (2022). "Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance". International Journal of Molecular Sciences (inglise). 23 (3): 1733. DOI:10.3390/ijms23031733. ISSN 1422-0067.
Guengerich, F. Peter (1. jaanuar 2021). "A history of the roles of cytochrome P450 enzymes in the toxicity of drugs". Toxicological Research (inglise). 37 (1): 1–23. DOI:10.1007/s43188-020-00056-z. ISSN 2234-2753. PMC 7431904. PMID 32837681.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Petrelli, Annalisa; Valabrega, Giorgio (1. märts 2009). "Multitarget drugs: the present and the future of cancer therapy". Expert Opinion on Pharmacotherapy. 10 (4): 589–600. DOI:10.1517/14656560902781907. ISSN 1465-6566. PMID 19284362.
Yumura, Masako; Nagano, Tatsuya; Nishimura, Yoshihiro (2020). "Novel Multitarget Therapies for Lung Cancer and Respiratory Disease". Molecules (inglise). 25 (17): 3987. DOI:10.3390/molecules25173987. ISSN 1420-3049.
Manley, P. W.; Cowan-Jacob, S. W.; Buchdunger, E.; Fabbro, D.; Fendrich, G.; Furet, P.; Meyer, T.; Zimmermann, J. (2002). "Imatinib: a selective tyrosine kinase inhibitor". European Journal of Cancer (Oxford, England: 1990). 38 Suppl 5: S19–27. DOI:10.1016/s0959-8049(02)80599-8. ISSN 0959-8049. PMID 12528769.
Cohen, Philip; Cross, Darren; Jänne, Pasi A. (2021). "Kinase drug discovery 20 years after imatinib: progress and future directions". Nature Reviews Drug Discovery (inglise). 20 (7): 551–569. DOI:10.1038/s41573-021-00195-4. ISSN 1474-1784.
Strumberg, Dirk (2005). "Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment". Drugs of Today (Barcelona, Spain: 1998). 41 (12): 773–784. DOI:10.1358/dot.2005.41.12.937959. ISSN 1699-3993. PMID 16474853.
Heudel, Pierre; Cassier, Philippe; Derbel, Olfa; Dufresne, Armelle; Meeus, Pierre; Thiesse, Philippe; Ranchère-Vince, Dominique; Blay, Jean Yves; Ray-Coquard, Isabelle (2012). "Pazopanib for the treatment of soft-tissue sarcoma". Clinical Pharmacology: Advances and Applications. 4: 65–70. DOI:10.2147/CPAA.S33195. ISSN 1179-1438. PMC 3508654. PMID 23204874.
Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian (2011). "The resurgence of covalent drugs". Nature Reviews Drug Discovery (inglise). 10 (4): 307–317. DOI:10.1038/nrd3410. ISSN 1474-1784.
Zhao, Zheng; Bourne, Philip E. (1. märts 2018). "Progress with covalent small-molecule kinase inhibitors". Drug Discovery Today (inglise). 23 (3): 727–735. DOI:10.1016/j.drudis.2018.01.035. ISSN 1359-6446.
Boike, Lydia; Henning, Nathaniel J.; Nomura, Daniel K. (2022). "Advances in covalent drug discovery". Nature Reviews Drug Discovery (inglise). 21 (12): 881–898. DOI:10.1038/s41573-022-00542-z. ISSN 1474-1784.
Roskoski, Robert (2021). "Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update". Pharmacological Research. 165: 105463. DOI:10.1016/j.phrs.2021.105463. ISSN 1096-1186. PMID 33513356.
Braun, Theodore P.; Eide, Christopher A.; Druker, Brian J. (13. aprill 2020). "Response and Resistance to BCR-ABL1-Targeted Therapies". Cancer Cell. 37 (4): 530–542. DOI:10.1016/j.ccell.2020.03.006. ISSN 1878-3686. PMC 7722523. PMID 32289275.
Soverini, Simona; De Benedittis, Caterina; Papayannidis, Cristina; Paolini, Stefania; Venturi, Claudia; Iacobucci, Ilaria; Luppi, Mario; Bresciani, Paola; Salvucci, Marzia; Russo, Domenico; Sica, Simona; Orlandi, Ester; Intermesoli, Tamara; Gozzini, Antonella; Bonifacio, Massimiliano (1. aprill 2014). "Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement". Cancer. 120 (7): 1002–1009. DOI:10.1002/cncr.28522. ISSN 1097-0142. PMID 24382642.
O'Hare, Thomas; Eide, Christopher A.; Deininger, Michael W. N. (1. oktoober 2007). "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia". Blood. 110 (7): 2242–2249. DOI:10.1182/blood-2007-03-066936. ISSN 0006-4971. PMID 17496200.
Vener, Claudia; Banzi, Rita; Ambrogi, Federico; Ferrero, Annalisa; Saglio, Giuseppe; Pravettoni, Gabriella; Sant, Milena (23. juuni 2020). "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis". Blood Advances. 4 (12): 2723–2735. DOI:10.1182/bloodadvances.2019001329. ISSN 2473-9537. PMC 7322957. PMID 32559295.
Stewart, Erin L.; Tan, Samuel Zhixing; Liu, Geoffrey; Tsao, Ming-Sound (2015). "Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review". Translational Lung Cancer Research (inglise). 4 (1). DOI:10.3978/j.issn.2218-6751.2014.11.06. ISSN 2226-4477.
Kim, Pora; Li, Hanyang; Wang, Junmei; Zhao, Zhongming (20. mai 2021). "Landscape of drug-resistance mutations in kinase regulatory hotspots". Briefings in Bioinformatics. 22 (3): bbaa108. DOI:10.1093/bib/bbaa108. ISSN 1477-4054. PMC 8138826. PMID 32510566.
He, Jingyi; Huang, Zhengrong; Han, Linzhi; Gong, Yan; Xie, Conghua (2021). "Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)". International Journal of Oncology. 59 (5): 90. DOI:10.3892/ijo.2021.5270. ISSN 1791-2423. PMC 8562388. PMID 34558640.
Sabnis, Amit J.; Bivona, Trever G. (2019). "Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology". Trends in Molecular Medicine. 25 (3): 185–197. DOI:10.1016/j.molmed.2018.12.009. ISSN 1471-499X. PMC 6401263. PMID 30686761.
Vander Velde, Robert; Yoon, Nara; Marusyk, Viktoriya; Durmaz, Arda; Dhawan, Andrew; Miroshnychenko, Daria; Lozano-Peral, Diego; Desai, Bina; Balynska, Olena; Poleszhuk, Jan; Kenian, Liu; Teng, Mingxiang; Abazeed, Mohamed; Mian, Omar; Tan, Aik Choon (14. mai 2020). "Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures". Nature Communications (inglise). 11 (1): 2393. DOI:10.1038/s41467-020-16212-w. ISSN 2041-1723.
Santhosh, Sam; Kumar, Prasanna; Ramprasad, Vedam; Chaudhuri, Amitabha (1. jaanuar 2015). "Evolution of targeted therapies in cancer: opportunities and challenges in the clinic". Future Oncology. 11 (2): 279–293. DOI:10.2217/fon.14.198. ISSN 1479-6694.
Kato, Shumei; Kim, Ki Hwan; Lim, Hyo Jeong; Boichard, Amelie; Nikanjam, Mina; Weihe, Elizabeth; Kuo, Dennis J.; Eskander, Ramez N.; Goodman, Aaron; Galanina, Natalie; Fanta, Paul T.; Schwab, Richard B.; Shatsky, Rebecca; Plaxe, Steven C.; Sharabi, Andrew (2. oktoober 2020). "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy". Nature Communications (inglise). 11 (1): 4965. DOI:10.1038/s41467-020-18613-3. ISSN 2041-1723.
Tamborero, David; Dienstmann, Rodrigo; Rachid, Maan Haj; Boekel, Jorrit; Lopez-Fernandez, Adria; Jonsson, Markus; Razzak, Ali; Braña, Irene; De Petris, Luigi; Yachnin, Jeffrey; Baird, Richard D.; Loriot, Yohann; Massard, Christophe; Martin-Romano, Patricia; Opdam, Frans (2022). "The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology". Nature Cancer (inglise). 3 (2): 251–261. DOI:10.1038/s43018-022-00332-x. ISSN 2662-1347.

ejcancer.com

Jordan, V. Craig (1. jaanuar 2008). "Tamoxifen: Catalyst for the change to targeted therapy". European Journal of Cancer (English). 44 (1): 30–38. DOI:10.1016/j.ejca.2007.11.002. ISSN 0959-8049.{{ajakirjaviide}}: CS1 hooldus: tundmatu keel (link)

epikoda.ee

sinuga.epikoda.ee

Koda, Eesti Puuetega Inimeste. "Personaalmeditsiin onkoloogias | Ajakiri Sinuga". sinuga.epikoda.ee. Vaadatud 11. veebruaril 2023.

europa.eu

ema.europa.eu

Euroopa Ravimiamet. "Rixathon, INN-rituximab" (PDF). ema.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "Enhertu, INN-trastuzumab deruxtecan" (PDF). ema.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "Vectibix, INN-panitumumab" (PDF). ema.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "Piqray, INN-alpelisib" (PDF). ema.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "Nexavar, INN-Sorafenib" (PDF). ema.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "Iressa, INN-gefitinib" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Herceptin, INN-trastuzumab" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Tyverb, INN-lapatinib" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Avastin, INN-bevacizumab" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Imatinib Accord, INN- Imatinib" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Imbruvica, INN-ibrutinib" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Inrebic, INN-fedratinib" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Zelboraf, INN-vemurafenib" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Afinitor, INN-everolimus" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Piqray, INN-alpelisib" (PDF). ema.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Lynparza (olapariib)" (PDF). ema.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "Venclyxto, INN-Venetoclax" (PDF). ema.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "Lumykras, INN-sotorasib" (PDF). ema.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "Votrient, INN-pazopanib" (PDF). ema.europa.eu. Vaadatud 05.02.2023.

ec.europa.eu

Euroopa Ravimiamet. "Mekinist, INN-trametinib" (PDF). ec.europa.eu. Vaadatud 05.02.2023.
Euroopa Ravimiamet. "XALKORI, INN-crizotinib" (PDF). ec.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Ibrance, INN-palbociclib" (PDF). ec.europa.eu. Vaadatud 22.02.2023.
Euroopa Ravimiamet. "Erivedge, INN-vismodegib" (PDF). ec.europa.eu. Vaadatud 05.02.2023.

frontiersin.org

Falzone, Luca; Salomone, Salvatore; Libra, Massimo (2018). "Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium". Frontiers in Pharmacology. 9. DOI:10.3389/fphar.2018.01300/full. ISSN 1663-9812.

futuremedicine.com

Santhosh, Sam; Kumar, Prasanna; Ramprasad, Vedam; Chaudhuri, Amitabha (1. jaanuar 2015). "Evolution of targeted therapies in cancer: opportunities and challenges in the clinic". Future Oncology. 11 (2): 279–293. DOI:10.2217/fon.14.198. ISSN 1479-6694.

illumina.com

Illumina (2016). "Technical Note: DNA Sequencing - Sequencing Panel for 4813 Genes with Known Associated Clinical Phenotypes" (PDF). illumina.com. Vaadatud 12.02.2023.

kingitudelu.ee

"Fondist". Kingitud Elu. Vaadatud 11. veebruaril 2023.

kliinikum.ee

"Moodustati molekulaarse onkogeneetika nõukoda". www.kliinikum.ee. Vaadatud 11. veebruaril 2023.

macmillan.org.uk

"Diabetes and targeted therapy - Macmillan Cancer Support". www.macmillan.org.uk (inglise). Vaadatud 5. veebruaril 2023.

mdpi.com

Constantinescu, Catalin; Pasca, Sergiu; Zimta, Alina-Andreea; Tat, Tiberiu; Rus, Ioana; Teodorescu, Patric; Iluta, Sabina; Tanase, Alina; Colita, Anca; Sigurjonsson, Olafur; Einsele, Hermann; Tomuleasa, Ciprian (2020). "Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies". Journal of Clinical Medicine (inglise). 9 (9): 2903. DOI:10.3390/jcm9092903. ISSN 2077-0383.
Zahavi, David; Weiner, Louis (2020). "Monoclonal Antibodies in Cancer Therapy". Antibodies (inglise). 9 (3): 34. DOI:10.3390/antib9030034. ISSN 2073-4468.
Nguyen, Ngoc Minh; Cho, Jungsook (2022). "Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance". International Journal of Molecular Sciences (inglise). 23 (3): 1733. DOI:10.3390/ijms23031733. ISSN 1422-0067.
Yumura, Masako; Nagano, Tatsuya; Nishimura, Yoshihiro (2020). "Novel Multitarget Therapies for Lung Cancer and Respiratory Disease". Molecules (inglise). 25 (17): 3987. DOI:10.3390/molecules25173987. ISSN 1420-3049.

mu.ee

"Kopsuvähi patsientide uuringutest oodatakse palju". www.mu.ee. 26. november 2021. Vaadatud 11. veebruaril 2023.

mycancergenome.org

"Targeted Therapies - My Cancer Genome". www.mycancergenome.org. Originaali arhiivikoopia seisuga 8. detsember 2022. Vaadatud 5. veebruaril 2023.

nature.com

Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong (31. mai 2021). "Small molecules in targeted cancer therapy: advances, challenges, and future perspectives". Signal Transduction and Targeted Therapy (inglise). 6 (1): 1–48. DOI:10.1038/s41392-021-00572-w. ISSN 2059-3635.
Cheng, Yuan; He, Cai; Wang, Manni; Ma, Xuelei; Mo, Fei; Yang, Shengyong; Han, Junhong; Wei, Xiawei (17. detsember 2019). "Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials". Signal Transduction and Targeted Therapy (inglise). 4 (1): 1–39. DOI:10.1038/s41392-019-0095-0. ISSN 2059-3635.
Huang, Lamei; Guo, Zhixing; Wang, Fang; Fu, Liwu (15. november 2021). "KRAS mutation: from undruggable to druggable in cancer". Signal Transduction and Targeted Therapy (inglise). 6 (1): 1–20. DOI:10.1038/s41392-021-00780-4. ISSN 2059-3635.
Cohen, Philip; Cross, Darren; Jänne, Pasi A. (2021). "Kinase drug discovery 20 years after imatinib: progress and future directions". Nature Reviews Drug Discovery (inglise). 20 (7): 551–569. DOI:10.1038/s41573-021-00195-4. ISSN 1474-1784.
Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian (2011). "The resurgence of covalent drugs". Nature Reviews Drug Discovery (inglise). 10 (4): 307–317. DOI:10.1038/nrd3410. ISSN 1474-1784.
Boike, Lydia; Henning, Nathaniel J.; Nomura, Daniel K. (2022). "Advances in covalent drug discovery". Nature Reviews Drug Discovery (inglise). 21 (12): 881–898. DOI:10.1038/s41573-022-00542-z. ISSN 1474-1784.
Vander Velde, Robert; Yoon, Nara; Marusyk, Viktoriya; Durmaz, Arda; Dhawan, Andrew; Miroshnychenko, Daria; Lozano-Peral, Diego; Desai, Bina; Balynska, Olena; Poleszhuk, Jan; Kenian, Liu; Teng, Mingxiang; Abazeed, Mohamed; Mian, Omar; Tan, Aik Choon (14. mai 2020). "Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures". Nature Communications (inglise). 11 (1): 2393. DOI:10.1038/s41467-020-16212-w. ISSN 2041-1723.
Kato, Shumei; Kim, Ki Hwan; Lim, Hyo Jeong; Boichard, Amelie; Nikanjam, Mina; Weihe, Elizabeth; Kuo, Dennis J.; Eskander, Ramez N.; Goodman, Aaron; Galanina, Natalie; Fanta, Paul T.; Schwab, Richard B.; Shatsky, Rebecca; Plaxe, Steven C.; Sharabi, Andrew (2. oktoober 2020). "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy". Nature Communications (inglise). 11 (1): 4965. DOI:10.1038/s41467-020-18613-3. ISSN 2041-1723.
Tamborero, David; Dienstmann, Rodrigo; Rachid, Maan Haj; Boekel, Jorrit; Lopez-Fernandez, Adria; Jonsson, Markus; Razzak, Ali; Braña, Irene; De Petris, Luigi; Yachnin, Jeffrey; Baird, Richard D.; Loriot, Yohann; Massard, Christophe; Martin-Romano, Patricia; Opdam, Frans (2022). "The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology". Nature Cancer (inglise). 3 (2): 251–261. DOI:10.1038/s43018-022-00332-x. ISSN 2662-1347.

nih.gov

pubmed.ncbi.nlm.nih.gov

Martinelli, E.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. (2009). "Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy". Clinical and Experimental Immunology. 158 (1): 1–9. DOI:10.1111/j.1365-2249.2009.03992.x. ISSN 1365-2249. PMC 2759052. PMID 19737224.
Baudino, Troy A. (2015). "Targeted Cancer Therapy: The Next Generation of Cancer Treatment". Current Drug Discovery Technologies. 12 (1): 3–20. DOI:10.2174/1570163812666150602144310. ISSN 1875-6220. PMID 26033233.
Phelps, Mitch A. (11. mai 2017). "Rituximab immunotherapy: it's getting personal". Blood. 129 (19): 2595–2596. DOI:10.1182/blood-2017-03-772061. ISSN 1528-0020. PMID 28495922.
Brown, Wells S.; McDonald, Paul C.; Nemirovsky, Oksana; Awrey, Shannon; Chafe, Shawn C.; Schaeffer, David F.; Li, Jinyang; Renouf, Daniel J.; Stanger, Ben Z.; Dedhar, Shoukat (17. november 2020). "Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer". Cell Reports Medicine (English). 1 (8). DOI:10.1016/j.xcrm.2020.100131. ISSN 2666-3791. PMID 33294856.{{ajakirjaviide}}: CS1 hooldus: tundmatu keel (link)
Bhullar, Khushwant S.; Lagarón, Naiara Orrego; McGowan, Eileen M.; Parmar, Indu; Jha, Amitabh; Hubbard, Basil P.; Rupasinghe, H. P. Vasantha (19. veebruar 2018). "Kinase-targeted cancer therapies: progress, challenges and future directions". Molecular Cancer. 17 (1): 48. DOI:10.1186/s12943-018-0804-2. ISSN 1476-4598. PMC 5817855. PMID 29455673.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Waring, Michael J. (15. mai 2009). "Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability". Bioorganic & Medicinal Chemistry Letters. 19 (10): 2844–2851. DOI:10.1016/j.bmcl.2009.03.109. ISSN 1464-3405. PMID 19361989.
Tangutoori, Shifalika; Baldwin, Paige; Sridhar, Srinivas (2015). "PARP inhibitors: A new era of targeted therapy". Maturitas. 81 (1): 5–9. DOI:10.1016/j.maturitas.2015.01.015. ISSN 1873-4111. PMID 25708226.
Perini, Guilherme Fleury; Ribeiro, Glaciano Nogueira; Pinto Neto, Jorge Vaz; Campos, Laura Tojeiro; Hamerschlak, Nelson (11. mai 2018). "BCL-2 as therapeutic target for hematological malignancies". Journal of Hematology & Oncology. 11 (1): 65. DOI:10.1186/s13045-018-0608-2. ISSN 1756-8722. PMC 5946445. PMID 29747654.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Guengerich, F. Peter (1. jaanuar 2021). "A history of the roles of cytochrome P450 enzymes in the toxicity of drugs". Toxicological Research (inglise). 37 (1): 1–23. DOI:10.1007/s43188-020-00056-z. ISSN 2234-2753. PMC 7431904. PMID 32837681.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Petrelli, Annalisa; Valabrega, Giorgio (1. märts 2009). "Multitarget drugs: the present and the future of cancer therapy". Expert Opinion on Pharmacotherapy. 10 (4): 589–600. DOI:10.1517/14656560902781907. ISSN 1465-6566. PMID 19284362.
Manley, P. W.; Cowan-Jacob, S. W.; Buchdunger, E.; Fabbro, D.; Fendrich, G.; Furet, P.; Meyer, T.; Zimmermann, J. (2002). "Imatinib: a selective tyrosine kinase inhibitor". European Journal of Cancer (Oxford, England: 1990). 38 Suppl 5: S19–27. DOI:10.1016/s0959-8049(02)80599-8. ISSN 0959-8049. PMID 12528769.
Strumberg, Dirk (2005). "Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment". Drugs of Today (Barcelona, Spain: 1998). 41 (12): 773–784. DOI:10.1358/dot.2005.41.12.937959. ISSN 1699-3993. PMID 16474853.
Heudel, Pierre; Cassier, Philippe; Derbel, Olfa; Dufresne, Armelle; Meeus, Pierre; Thiesse, Philippe; Ranchère-Vince, Dominique; Blay, Jean Yves; Ray-Coquard, Isabelle (2012). "Pazopanib for the treatment of soft-tissue sarcoma". Clinical Pharmacology: Advances and Applications. 4: 65–70. DOI:10.2147/CPAA.S33195. ISSN 1179-1438. PMC 3508654. PMID 23204874.
Roskoski, Robert (2021). "Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update". Pharmacological Research. 165: 105463. DOI:10.1016/j.phrs.2021.105463. ISSN 1096-1186. PMID 33513356.
Braun, Theodore P.; Eide, Christopher A.; Druker, Brian J. (13. aprill 2020). "Response and Resistance to BCR-ABL1-Targeted Therapies". Cancer Cell. 37 (4): 530–542. DOI:10.1016/j.ccell.2020.03.006. ISSN 1878-3686. PMC 7722523. PMID 32289275.
Soverini, Simona; De Benedittis, Caterina; Papayannidis, Cristina; Paolini, Stefania; Venturi, Claudia; Iacobucci, Ilaria; Luppi, Mario; Bresciani, Paola; Salvucci, Marzia; Russo, Domenico; Sica, Simona; Orlandi, Ester; Intermesoli, Tamara; Gozzini, Antonella; Bonifacio, Massimiliano (1. aprill 2014). "Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement". Cancer. 120 (7): 1002–1009. DOI:10.1002/cncr.28522. ISSN 1097-0142. PMID 24382642.
O'Hare, Thomas; Eide, Christopher A.; Deininger, Michael W. N. (1. oktoober 2007). "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia". Blood. 110 (7): 2242–2249. DOI:10.1182/blood-2007-03-066936. ISSN 0006-4971. PMID 17496200.
Vener, Claudia; Banzi, Rita; Ambrogi, Federico; Ferrero, Annalisa; Saglio, Giuseppe; Pravettoni, Gabriella; Sant, Milena (23. juuni 2020). "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis". Blood Advances. 4 (12): 2723–2735. DOI:10.1182/bloodadvances.2019001329. ISSN 2473-9537. PMC 7322957. PMID 32559295.
Kim, Pora; Li, Hanyang; Wang, Junmei; Zhao, Zhongming (20. mai 2021). "Landscape of drug-resistance mutations in kinase regulatory hotspots". Briefings in Bioinformatics. 22 (3): bbaa108. DOI:10.1093/bib/bbaa108. ISSN 1477-4054. PMC 8138826. PMID 32510566.
He, Jingyi; Huang, Zhengrong; Han, Linzhi; Gong, Yan; Xie, Conghua (2021). "Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)". International Journal of Oncology. 59 (5): 90. DOI:10.3892/ijo.2021.5270. ISSN 1791-2423. PMC 8562388. PMID 34558640.
Sabnis, Amit J.; Bivona, Trever G. (2019). "Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology". Trends in Molecular Medicine. 25 (3): 185–197. DOI:10.1016/j.molmed.2018.12.009. ISSN 1471-499X. PMC 6401263. PMID 30686761.

ncbi.nlm.nih.gov

Martinelli, E.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. (2009). "Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy". Clinical and Experimental Immunology. 158 (1): 1–9. DOI:10.1111/j.1365-2249.2009.03992.x. ISSN 1365-2249. PMC 2759052. PMID 19737224.
Bhullar, Khushwant S.; Lagarón, Naiara Orrego; McGowan, Eileen M.; Parmar, Indu; Jha, Amitabh; Hubbard, Basil P.; Rupasinghe, H. P. Vasantha (19. veebruar 2018). "Kinase-targeted cancer therapies: progress, challenges and future directions". Molecular Cancer. 17 (1): 48. DOI:10.1186/s12943-018-0804-2. ISSN 1476-4598. PMC 5817855. PMID 29455673.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Perini, Guilherme Fleury; Ribeiro, Glaciano Nogueira; Pinto Neto, Jorge Vaz; Campos, Laura Tojeiro; Hamerschlak, Nelson (11. mai 2018). "BCL-2 as therapeutic target for hematological malignancies". Journal of Hematology & Oncology. 11 (1): 65. DOI:10.1186/s13045-018-0608-2. ISSN 1756-8722. PMC 5946445. PMID 29747654.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Guengerich, F. Peter (1. jaanuar 2021). "A history of the roles of cytochrome P450 enzymes in the toxicity of drugs". Toxicological Research (inglise). 37 (1): 1–23. DOI:10.1007/s43188-020-00056-z. ISSN 2234-2753. PMC 7431904. PMID 32837681.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Heudel, Pierre; Cassier, Philippe; Derbel, Olfa; Dufresne, Armelle; Meeus, Pierre; Thiesse, Philippe; Ranchère-Vince, Dominique; Blay, Jean Yves; Ray-Coquard, Isabelle (2012). "Pazopanib for the treatment of soft-tissue sarcoma". Clinical Pharmacology: Advances and Applications. 4: 65–70. DOI:10.2147/CPAA.S33195. ISSN 1179-1438. PMC 3508654. PMID 23204874.
Braun, Theodore P.; Eide, Christopher A.; Druker, Brian J. (13. aprill 2020). "Response and Resistance to BCR-ABL1-Targeted Therapies". Cancer Cell. 37 (4): 530–542. DOI:10.1016/j.ccell.2020.03.006. ISSN 1878-3686. PMC 7722523. PMID 32289275.
Vener, Claudia; Banzi, Rita; Ambrogi, Federico; Ferrero, Annalisa; Saglio, Giuseppe; Pravettoni, Gabriella; Sant, Milena (23. juuni 2020). "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis". Blood Advances. 4 (12): 2723–2735. DOI:10.1182/bloodadvances.2019001329. ISSN 2473-9537. PMC 7322957. PMID 32559295.
Kim, Pora; Li, Hanyang; Wang, Junmei; Zhao, Zhongming (20. mai 2021). "Landscape of drug-resistance mutations in kinase regulatory hotspots". Briefings in Bioinformatics. 22 (3): bbaa108. DOI:10.1093/bib/bbaa108. ISSN 1477-4054. PMC 8138826. PMID 32510566.
He, Jingyi; Huang, Zhengrong; Han, Linzhi; Gong, Yan; Xie, Conghua (2021). "Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)". International Journal of Oncology. 59 (5): 90. DOI:10.3892/ijo.2021.5270. ISSN 1791-2423. PMC 8562388. PMID 34558640.
Sabnis, Amit J.; Bivona, Trever G. (2019). "Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology". Trends in Molecular Medicine. 25 (3): 185–197. DOI:10.1016/j.molmed.2018.12.009. ISSN 1471-499X. PMC 6401263. PMID 30686761.

postimees.ee

tervis.postimees.ee

"Onkoloog: vähiravi peaksid saama ka ravikindlustuseta inimesed". Haigused. 27. veebruar 2017. Vaadatud 11. veebruaril 2023.

ravimiregister.ee

Ravimiregister. "Tamoxifen „Ebewe"" (PDF). ravimiregister.ee. Vaadatud 05.02.2023.
Ravimiregister. "Bortezomib Ebewe" (PDF). ravimiregister.ee. Vaadatud 05.02.2023.

sciencedirect.com

Zhao, Zheng; Bourne, Philip E. (1. märts 2018). "Progress with covalent small-molecule kinase inhibitors". Drug Discovery Today (inglise). 23 (3): 727–735. DOI:10.1016/j.drudis.2018.01.035. ISSN 1359-6446.

utlib.ee

ojs.utlib.ee

Roht, Laura; Laidre, Piret; Kahre, Tiina; Õunap, Katrin (25. oktoober 2021). "Onkoloogilised konsultatsioonid meditsiinigeneetikas: näidustused ja kliiniline praktika". Eesti Arst (inglise). ISSN 2228-1665.
Ojamaa, Kristiina; Kuusk, Gerli (21. juuni 2021). "Kasvajate molekulaarse diagnostika ja molekulaarse kasvajakonsiiliumi lõimimine kliinilisse praktikasse". Eesti Arst (inglise). ISSN 2228-1665.

vahigeenid.ee

Habarov, Aleksei (17. mai 2021). "Onkoloog dr Kersti Oselin: vähigeeni testide kasutuselevõtt on parandanud arusaamist vähi bioloogiast ja ka haiguse ravist". Vähigeenid. Originaali arhiivikoopia seisuga 11. veebruar 2023. Vaadatud 11. veebruaril 2023.

web.archive.org

"Targeted Therapies - My Cancer Genome". www.mycancergenome.org. Originaali arhiivikoopia seisuga 8. detsember 2022. Vaadatud 5. veebruaril 2023.
Habarov, Aleksei (17. mai 2021). "Onkoloog dr Kersti Oselin: vähigeeni testide kasutuselevõtt on parandanud arusaamist vähi bioloogiast ja ka haiguse ravist". Vähigeenid. Originaali arhiivikoopia seisuga 11. veebruar 2023. Vaadatud 11. veebruaril 2023.

worldcat.org

Martinelli, E.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. (2009). "Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy". Clinical and Experimental Immunology. 158 (1): 1–9. DOI:10.1111/j.1365-2249.2009.03992.x. ISSN 1365-2249. PMC 2759052. PMID 19737224.
Falzone, Luca; Salomone, Salvatore; Libra, Massimo (2018). "Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium". Frontiers in Pharmacology. 9. DOI:10.3389/fphar.2018.01300/full. ISSN 1663-9812.
Baudino, Troy A. (2015). "Targeted Cancer Therapy: The Next Generation of Cancer Treatment". Current Drug Discovery Technologies. 12 (1): 3–20. DOI:10.2174/1570163812666150602144310. ISSN 1875-6220. PMID 26033233.
Phelps, Mitch A. (11. mai 2017). "Rituximab immunotherapy: it's getting personal". Blood. 129 (19): 2595–2596. DOI:10.1182/blood-2017-03-772061. ISSN 1528-0020. PMID 28495922.
Jordan, V. Craig (1. jaanuar 2008). "Tamoxifen: Catalyst for the change to targeted therapy". European Journal of Cancer (English). 44 (1): 30–38. DOI:10.1016/j.ejca.2007.11.002. ISSN 0959-8049.{{ajakirjaviide}}: CS1 hooldus: tundmatu keel (link)
Zhong, Lei; Li, Yueshan; Xiong, Liang; Wang, Wenjing; Wu, Ming; Yuan, Ting; Yang, Wei; Tian, Chenyu; Miao, Zhuang; Wang, Tianqi; Yang, Shengyong (31. mai 2021). "Small molecules in targeted cancer therapy: advances, challenges, and future perspectives". Signal Transduction and Targeted Therapy (inglise). 6 (1): 1–48. DOI:10.1038/s41392-021-00572-w. ISSN 2059-3635.
Constantinescu, Catalin; Pasca, Sergiu; Zimta, Alina-Andreea; Tat, Tiberiu; Rus, Ioana; Teodorescu, Patric; Iluta, Sabina; Tanase, Alina; Colita, Anca; Sigurjonsson, Olafur; Einsele, Hermann; Tomuleasa, Ciprian (2020). "Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies". Journal of Clinical Medicine (inglise). 9 (9): 2903. DOI:10.3390/jcm9092903. ISSN 2077-0383.
Brown, Wells S.; McDonald, Paul C.; Nemirovsky, Oksana; Awrey, Shannon; Chafe, Shawn C.; Schaeffer, David F.; Li, Jinyang; Renouf, Daniel J.; Stanger, Ben Z.; Dedhar, Shoukat (17. november 2020). "Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer". Cell Reports Medicine (English). 1 (8). DOI:10.1016/j.xcrm.2020.100131. ISSN 2666-3791. PMID 33294856.{{ajakirjaviide}}: CS1 hooldus: tundmatu keel (link)
Bhullar, Khushwant S.; Lagarón, Naiara Orrego; McGowan, Eileen M.; Parmar, Indu; Jha, Amitabh; Hubbard, Basil P.; Rupasinghe, H. P. Vasantha (19. veebruar 2018). "Kinase-targeted cancer therapies: progress, challenges and future directions". Molecular Cancer. 17 (1): 48. DOI:10.1186/s12943-018-0804-2. ISSN 1476-4598. PMC 5817855. PMID 29455673.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Waring, Michael J. (15. mai 2009). "Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability". Bioorganic & Medicinal Chemistry Letters. 19 (10): 2844–2851. DOI:10.1016/j.bmcl.2009.03.109. ISSN 1464-3405. PMID 19361989.
Zahavi, David; Weiner, Louis (2020). "Monoclonal Antibodies in Cancer Therapy". Antibodies (inglise). 9 (3): 34. DOI:10.3390/antib9030034. ISSN 2073-4468.
Tangutoori, Shifalika; Baldwin, Paige; Sridhar, Srinivas (2015). "PARP inhibitors: A new era of targeted therapy". Maturitas. 81 (1): 5–9. DOI:10.1016/j.maturitas.2015.01.015. ISSN 1873-4111. PMID 25708226.
Perini, Guilherme Fleury; Ribeiro, Glaciano Nogueira; Pinto Neto, Jorge Vaz; Campos, Laura Tojeiro; Hamerschlak, Nelson (11. mai 2018). "BCL-2 as therapeutic target for hematological malignancies". Journal of Hematology & Oncology. 11 (1): 65. DOI:10.1186/s13045-018-0608-2. ISSN 1756-8722. PMC 5946445. PMID 29747654.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Cheng, Yuan; He, Cai; Wang, Manni; Ma, Xuelei; Mo, Fei; Yang, Shengyong; Han, Junhong; Wei, Xiawei (17. detsember 2019). "Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials". Signal Transduction and Targeted Therapy (inglise). 4 (1): 1–39. DOI:10.1038/s41392-019-0095-0. ISSN 2059-3635.
Huang, Lamei; Guo, Zhixing; Wang, Fang; Fu, Liwu (15. november 2021). "KRAS mutation: from undruggable to druggable in cancer". Signal Transduction and Targeted Therapy (inglise). 6 (1): 1–20. DOI:10.1038/s41392-021-00780-4. ISSN 2059-3635.
Nguyen, Ngoc Minh; Cho, Jungsook (2022). "Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance". International Journal of Molecular Sciences (inglise). 23 (3): 1733. DOI:10.3390/ijms23031733. ISSN 1422-0067.
Guengerich, F. Peter (1. jaanuar 2021). "A history of the roles of cytochrome P450 enzymes in the toxicity of drugs". Toxicological Research (inglise). 37 (1): 1–23. DOI:10.1007/s43188-020-00056-z. ISSN 2234-2753. PMC 7431904. PMID 32837681.{{ajakirjaviide}}: CS1 hooldus: PMC vormistus (link)
Petrelli, Annalisa; Valabrega, Giorgio (1. märts 2009). "Multitarget drugs: the present and the future of cancer therapy". Expert Opinion on Pharmacotherapy. 10 (4): 589–600. DOI:10.1517/14656560902781907. ISSN 1465-6566. PMID 19284362.
Yumura, Masako; Nagano, Tatsuya; Nishimura, Yoshihiro (2020). "Novel Multitarget Therapies for Lung Cancer and Respiratory Disease". Molecules (inglise). 25 (17): 3987. DOI:10.3390/molecules25173987. ISSN 1420-3049.
Manley, P. W.; Cowan-Jacob, S. W.; Buchdunger, E.; Fabbro, D.; Fendrich, G.; Furet, P.; Meyer, T.; Zimmermann, J. (2002). "Imatinib: a selective tyrosine kinase inhibitor". European Journal of Cancer (Oxford, England: 1990). 38 Suppl 5: S19–27. DOI:10.1016/s0959-8049(02)80599-8. ISSN 0959-8049. PMID 12528769.
Cohen, Philip; Cross, Darren; Jänne, Pasi A. (2021). "Kinase drug discovery 20 years after imatinib: progress and future directions". Nature Reviews Drug Discovery (inglise). 20 (7): 551–569. DOI:10.1038/s41573-021-00195-4. ISSN 1474-1784.
Strumberg, Dirk (2005). "Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment". Drugs of Today (Barcelona, Spain: 1998). 41 (12): 773–784. DOI:10.1358/dot.2005.41.12.937959. ISSN 1699-3993. PMID 16474853.
Heudel, Pierre; Cassier, Philippe; Derbel, Olfa; Dufresne, Armelle; Meeus, Pierre; Thiesse, Philippe; Ranchère-Vince, Dominique; Blay, Jean Yves; Ray-Coquard, Isabelle (2012). "Pazopanib for the treatment of soft-tissue sarcoma". Clinical Pharmacology: Advances and Applications. 4: 65–70. DOI:10.2147/CPAA.S33195. ISSN 1179-1438. PMC 3508654. PMID 23204874.
Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian (2011). "The resurgence of covalent drugs". Nature Reviews Drug Discovery (inglise). 10 (4): 307–317. DOI:10.1038/nrd3410. ISSN 1474-1784.
Zhao, Zheng; Bourne, Philip E. (1. märts 2018). "Progress with covalent small-molecule kinase inhibitors". Drug Discovery Today (inglise). 23 (3): 727–735. DOI:10.1016/j.drudis.2018.01.035. ISSN 1359-6446.
Boike, Lydia; Henning, Nathaniel J.; Nomura, Daniel K. (2022). "Advances in covalent drug discovery". Nature Reviews Drug Discovery (inglise). 21 (12): 881–898. DOI:10.1038/s41573-022-00542-z. ISSN 1474-1784.
Roskoski, Robert (2021). "Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update". Pharmacological Research. 165: 105463. DOI:10.1016/j.phrs.2021.105463. ISSN 1096-1186. PMID 33513356.
Braun, Theodore P.; Eide, Christopher A.; Druker, Brian J. (13. aprill 2020). "Response and Resistance to BCR-ABL1-Targeted Therapies". Cancer Cell. 37 (4): 530–542. DOI:10.1016/j.ccell.2020.03.006. ISSN 1878-3686. PMC 7722523. PMID 32289275.
Soverini, Simona; De Benedittis, Caterina; Papayannidis, Cristina; Paolini, Stefania; Venturi, Claudia; Iacobucci, Ilaria; Luppi, Mario; Bresciani, Paola; Salvucci, Marzia; Russo, Domenico; Sica, Simona; Orlandi, Ester; Intermesoli, Tamara; Gozzini, Antonella; Bonifacio, Massimiliano (1. aprill 2014). "Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement". Cancer. 120 (7): 1002–1009. DOI:10.1002/cncr.28522. ISSN 1097-0142. PMID 24382642.
O'Hare, Thomas; Eide, Christopher A.; Deininger, Michael W. N. (1. oktoober 2007). "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia". Blood. 110 (7): 2242–2249. DOI:10.1182/blood-2007-03-066936. ISSN 0006-4971. PMID 17496200.
Vener, Claudia; Banzi, Rita; Ambrogi, Federico; Ferrero, Annalisa; Saglio, Giuseppe; Pravettoni, Gabriella; Sant, Milena (23. juuni 2020). "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis". Blood Advances. 4 (12): 2723–2735. DOI:10.1182/bloodadvances.2019001329. ISSN 2473-9537. PMC 7322957. PMID 32559295.
Stewart, Erin L.; Tan, Samuel Zhixing; Liu, Geoffrey; Tsao, Ming-Sound (2015). "Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review". Translational Lung Cancer Research (inglise). 4 (1). DOI:10.3978/j.issn.2218-6751.2014.11.06. ISSN 2226-4477.
Kim, Pora; Li, Hanyang; Wang, Junmei; Zhao, Zhongming (20. mai 2021). "Landscape of drug-resistance mutations in kinase regulatory hotspots". Briefings in Bioinformatics. 22 (3): bbaa108. DOI:10.1093/bib/bbaa108. ISSN 1477-4054. PMC 8138826. PMID 32510566.
He, Jingyi; Huang, Zhengrong; Han, Linzhi; Gong, Yan; Xie, Conghua (2021). "Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)". International Journal of Oncology. 59 (5): 90. DOI:10.3892/ijo.2021.5270. ISSN 1791-2423. PMC 8562388. PMID 34558640.
Sabnis, Amit J.; Bivona, Trever G. (2019). "Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology". Trends in Molecular Medicine. 25 (3): 185–197. DOI:10.1016/j.molmed.2018.12.009. ISSN 1471-499X. PMC 6401263. PMID 30686761.
Vander Velde, Robert; Yoon, Nara; Marusyk, Viktoriya; Durmaz, Arda; Dhawan, Andrew; Miroshnychenko, Daria; Lozano-Peral, Diego; Desai, Bina; Balynska, Olena; Poleszhuk, Jan; Kenian, Liu; Teng, Mingxiang; Abazeed, Mohamed; Mian, Omar; Tan, Aik Choon (14. mai 2020). "Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures". Nature Communications (inglise). 11 (1): 2393. DOI:10.1038/s41467-020-16212-w. ISSN 2041-1723.
Santhosh, Sam; Kumar, Prasanna; Ramprasad, Vedam; Chaudhuri, Amitabha (1. jaanuar 2015). "Evolution of targeted therapies in cancer: opportunities and challenges in the clinic". Future Oncology. 11 (2): 279–293. DOI:10.2217/fon.14.198. ISSN 1479-6694.
Roht, Laura; Laidre, Piret; Kahre, Tiina; Õunap, Katrin (25. oktoober 2021). "Onkoloogilised konsultatsioonid meditsiinigeneetikas: näidustused ja kliiniline praktika". Eesti Arst (inglise). ISSN 2228-1665.
Kato, Shumei; Kim, Ki Hwan; Lim, Hyo Jeong; Boichard, Amelie; Nikanjam, Mina; Weihe, Elizabeth; Kuo, Dennis J.; Eskander, Ramez N.; Goodman, Aaron; Galanina, Natalie; Fanta, Paul T.; Schwab, Richard B.; Shatsky, Rebecca; Plaxe, Steven C.; Sharabi, Andrew (2. oktoober 2020). "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy". Nature Communications (inglise). 11 (1): 4965. DOI:10.1038/s41467-020-18613-3. ISSN 2041-1723.
Tamborero, David; Dienstmann, Rodrigo; Rachid, Maan Haj; Boekel, Jorrit; Lopez-Fernandez, Adria; Jonsson, Markus; Razzak, Ali; Braña, Irene; De Petris, Luigi; Yachnin, Jeffrey; Baird, Richard D.; Loriot, Yohann; Massard, Christophe; Martin-Romano, Patricia; Opdam, Frans (2022). "The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology". Nature Cancer (inglise). 3 (2): 251–261. DOI:10.1038/s43018-022-00332-x. ISSN 2662-1347.
Ojamaa, Kristiina; Kuusk, Gerli (21. juuni 2021). "Kasvajate molekulaarse diagnostika ja molekulaarse kasvajakonsiiliumi lõimimine kliinilisse praktikasse". Eesti Arst (inglise). ISSN 2228-1665.